107 related articles for article (PubMed ID: 22824926)
1. SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression.
Wang H; Wu R; Yu L; Wu F; Li S; Zhao Y; Li H; Luo G; Wang J; Zhou J
Oncol Rep; 2012 Oct; 28(4):1468-74. PubMed ID: 22824926
[TBL] [Abstract][Full Text] [Related]
2. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
3. Isolation of the novel human guanine nucleotide exchange factor Src homology 3 domain-containing guanine nucleotide exchange factor (SGEF) and of C-terminal SGEF, an N-terminally truncated form of SGEF, the expression of which is regulated by androgen in prostate cancer cells.
Qi H; Fournier A; Grenier J; Fillion C; Labrie Y; Labrie C
Endocrinology; 2003 May; 144(5):1742-52. PubMed ID: 12697679
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy.
Zhang K; Yan F; Lei X; Wei D; Lu H; Zhu Z; Xiang A; Ye Z; Wang L; Zheng W; Li X; Yuan J; Lu Z; Yuan J
Mol Med Rep; 2018 Jun; 17(6):8203-8211. PubMed ID: 29658587
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
Desiniotis A; Schäfer G; Klocker H; Eder IE
Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
7. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.
Harada N; Inoue K; Yamaji R; Nakano Y; Inui H
Cancer Sci; 2012 Jun; 103(6):1022-7. PubMed ID: 22360658
[TBL] [Abstract][Full Text] [Related]
9. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Jin F; Fondell JD
Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
11. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
12. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.
Wang T; Guo S; Liu Z; Wu L; Li M; Yang J; Chen R; Liu X; Xu H; Cai S; Chen H; Li W; Xu S; Wang L; Hu Z; Zhuang Q; Wang L; Wu K; Liu J; Ye Z; Ji JY; Wang C; Chen K
Oncotarget; 2014 Nov; 5(21):10293-306. PubMed ID: 25296973
[TBL] [Abstract][Full Text] [Related]
13. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
14. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
16. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
18. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
19. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
20. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]